DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis

Papers of special note have been highlighted as: ▪ of interest

References

• 1  Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin. Cancer Res.5(9),2289–2296 (1999).
  Medline CASGoogle Scholar
• 2  Walko CM, Lindley C. Capecitabine: a review. Clin. Ther.27(1),23–44 (2005).
  Medline CASGoogle Scholar
• 3  Chau I, Norman AR, Cunningham D et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann. Oncol.16(4),549–557 (2005).
  Medline CASGoogle Scholar
• 4  Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist7(4),288–323 (2002).
  Medline CASGoogle Scholar
• 5  van Kuilenburg AB. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that’s the question. Cancer Invest.24(2),215–217 (2006).
  MedlineGoogle Scholar
• 6  Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics12(9),1321–1336 (2011).▪ Recent comprehensive descriptive review on 5-fluorouracil pharmacogenetics.
  CASGoogle Scholar
• 7  Vreken P, van Kuilenburg AB, Meinsma R et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J. Inherit. Metab. Dis.19(5),645–654 (1996).
  Medline CASGoogle Scholar
• 8  Wei X, McLeod HL, McMurrough J et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest.98(3),610–615 (1996).
  Medline CASGoogle Scholar
• 9  Morel A, Boisdron-Celle M, Fey L et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther.5(11),2895–2904 (2006).▪ First large prospective study focusing on the impact of DPYD variants on the risk of severe fluoropyrimidine-related toxicity.
  Medline CASGoogle Scholar
• 10  Boisdron-Celle M, Remaud G, Traore S et al. 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett.249(2),271–282 (2007).
  Medline CASGoogle Scholar
• 11  Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol.26(13),2131–2138 (2008).▪ Largest prospective study investigating DPYD variants in the context of 5-fluorouracil toxicity.
  Medline CASGoogle Scholar
• 12  Braun MS, Richman SD, Thompson L et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J. Clin. Oncol.27(33),5519–5528 (2009).
  Medline CASGoogle Scholar
• 13  Amstutz U, Farese S, Aebi S, Largiadèr CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics10(6),931–944 (2009).
  CASGoogle Scholar
• 14  Gross E, Busse B, Riemenschneider M et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One3(12),e4003 (2008).
  MedlineGoogle Scholar
• 15  van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics12(7),555–558 (2002).
  Medline CASGoogle Scholar
• 16  Salgueiro N, Veiga I, Fragoso M et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet. Med.6(2),102–107 (2004).
  Medline CASGoogle Scholar
• 17  van Kuilenburg AB, Haasjes J, Richel DJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res.6(12),4705–4712 (2000).
  Medline CASGoogle Scholar
• 18  Mattison L, Johnson MR, Diasio R. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics12(2),133–144 (2002).
  Medline CASGoogle Scholar
• 19  Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J. Clin. Oncol.16(11),3537–3541 (1998).
  Medline CASGoogle Scholar
• 20  Chansky K, Benedetti J, MacDonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer103(6),1165–1171 (2005).
  Medline CASGoogle Scholar
• 21  Little J, Higgins JP, Ioannidis JP et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE statement. Ann. Intern. Med.150(3),206–215 (2009).
  MedlineGoogle Scholar
• 22  DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials7(3),177–188 (1986).
  Medline CASGoogle Scholar
• 23  Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches. J. Clin. Epidemiol.61(7),634–645 (2008).
  MedlineGoogle Scholar
• 24  Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann. Intern. Med.127(9),820–826 (1997).
  Medline CASGoogle Scholar
• 25  Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ315(7109),629–634 (1997).
  Medline CASGoogle Scholar
• 26  Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat. Med.25(20),3443–3457 (2006).
  MedlineGoogle Scholar
• 27  Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics50(4),1088–1101 (1994).
  Medline CASGoogle Scholar
• 28  Largillier R, Etienne-Grimaldi MC, Formento JL et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res.12(18),5496–5502 (2006).
  Medline CASGoogle Scholar
• 29  Sulzyc-Bielicka V, Bińczak-Kuleta A, Pioch W et al. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol. Rep.60(2),238–242 (2008).
  Medline CASGoogle Scholar
• 30  Kleibl Z, Fidlerova J, Kleiblova P et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma56(4),303–316 (2009).
  Medline CASGoogle Scholar
• 31  Boige V, Mendiboure J, Pignon JP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol.28(15),2556–2564 (2010).
  Medline CASGoogle Scholar
• 32  Kristensen MH, Pedersen PL, Melsen GV, Ellehauge J, Mejer J. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J. Int. Med. Res.38(3),870–883 (2010).
  Medline CASGoogle Scholar
• 33  Cerić T, Obralić N, Kapur-Pojskić L et al. Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-fluorouracil and capecitabine. Bosn. J. Basic Med. Sci.10(2),133–139 (2010).
  Medline CASGoogle Scholar
• 34  Cellier P, Leduc B, Martin L et al. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer11,98 (2011).
  Medline CASGoogle Scholar
• 35  Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res.17(10),3455–3468 (2011).
  Medline CASGoogle Scholar
• 36  Cho HJ, Park YS, Kang WK, Kim JW, Lee SY. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther. Drug. Monit.29(2),190–196 (2007).
  Medline CASGoogle Scholar
• 37  Maekawa K, Saeki M, Saito Y et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J. Hum. Genet.52(10),804–819 (2007).
  Medline CASGoogle Scholar
• 38  Sutton AJ, Cooper NJ, Lambert PC, Jones DR, Abrams KR, Sweeting MJ. Meta-analysis of rare and adverse event data. Expert Rev. Pharmacoecon. Outcomes Res.2(4),367–379 (2002).
  MedlineGoogle Scholar
• 39  Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin. Pharmacol. Ther.89(5),662–673 (2011).
  Medline CASGoogle Scholar
• 40  Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J. Clin. Oncol.16(11),3537–3541 (1998).
  Medline CASGoogle Scholar
• 41  Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin. Cancer Res.9(8),3021–3028 (2003).
  Medline CASGoogle Scholar
• 42  van Kuilenburg AB, Dobritzsch D, Meinsma R et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem. J.364(Pt 1),157–163 (2002).
  Medline CASGoogle Scholar
• 43  Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res.8(3),768–774 (2002).
  Medline CASGoogle Scholar
• 44  Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, Marinaki AM. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother. Pharmacol.65(2),403–406 (2010).
  Medline CASGoogle Scholar
• 45  Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res.11(24 Pt 1),8699–8705 (2005).
  Medline CASGoogle Scholar
• 46  Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics10(3),217–223 (2000).
  Medline CASGoogle Scholar
• 47  Savva-Bordalo J, Ramalho-Carvalho J, Pinheiro M et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer10,470 (2010).
  Medline CASGoogle Scholar
• 48  Amstutz U, Farese S, Aebi S, Largiadèr CR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J. Exp. Clin. Cancer Res.27(1),54 (2008).
  MedlineGoogle Scholar
• 49  Ticha I, Kleiblova P, Fidlerova J, Novotny J, Pohlreich P, Kleibl Z. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity. Cancer Chemother. Pharmacol.64(3),615–618 (2009).
  Medline CASGoogle Scholar
• 50  Paré L, Paez D, Salazar J et al. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. Br. J. Clin. Pharmacol.70(2),268–272 (2010).
  Medline CASGoogle Scholar
• 51  Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin. Colorectal Cancer6(4),288–296 (2006).▪ Comprehensive review on phenotypic methods for DPD status evaluation.
  Medline CASGoogle Scholar
• 52  van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, van Kuilenburg AB, Maring JG. Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother. Pharmacol.68(6),1611–1617 (2011).
  Medline CASGoogle Scholar
• 53  Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal Cancer9(4),224–228 (2010).
  Medline CASGoogle Scholar
• 54  Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet. Genomics22(4),290–304 (2012).▪ Recent meta-analysis of TYMS 5´-UTR repeat and MTHFR 677C>T polymorphisms and risk of adverse effects in fluoropyrimidine-treated colorectal cancer patients.
  Medline CASGoogle Scholar
• 55  Afzal S, Gusella M, Vainer B et al. Combinations of polymorphisms in genes involved in the 5-fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin. Cancer Res.17(11),3822–3829 (2011).
  Medline CASGoogle Scholar
• 101  Little J, Higgins JP (Eds). The HuGENet™ HuGE Review Handbook, Version 1.0. Ottawa, Ontario, Canada: HuGENet Canada Coordinating Centre (2006). www.medicine.uottawa.ca/public-health-genomics/web/assets/documents/HuGE_Review_Handbook_V1_0.pdf (Accessed 12 July 2012)
  Google Scholar
• 102  Open Meta-Analyst. http://tuftscaes.org/open_meta
  Google Scholar